Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
Mené en Chine sur 102 patients atteints d'un cancer du poumon non à petites cellules de stade IIIA présentant une mutation EGFR, cet essai de phase II compare l'efficacité, du point de vue de la survie sans maladie à 2 ans, et la toxicité de l'erlotinib et d'une chimiothérapie à base de vinorelbine et de cisplatine (durée médiane de suivi : 33 mois)
Non-small-cell lung cancers (NSCLCs) harbour several mutations that drive tumour progression, and these aberrations can be effectively inhibited by small-molecule tyrosine kinase inhibitors (TKIs). Mutations in the epidermal growth factor receptor (EGFR) are the most common druggable alterations in NSCLC. The apparent activity of gefitinib—a first-generation EGFR TKI—in NSCLC was already shown in 2003. Since then, next-generation EGFR TKIs, which are more potent and can overcome resistance mechanisms, have been developed. At present, EGFR TKIs are considered the first- and second-line treatment of choice for patients with EGFR-mutant advanced NSCLC.